Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.
Recent developments in the biopharmaceutical world have brought attention to Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). The law firm Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit that seeks to represent individuals who purchased or acquired common stock of Ultragenyx between certain specified periods. This lawsuit highlights the responsibilities of companies to provide accurate information to their investors.
Overview of the Allegations
The allegations center around claims that Ultragenyx and its executives made misleading statements during the period, creating a false narrative regarding the effects of their treatment, setrusumab, particularly for Osteogenesis Imperfecta (OI). Investors were reportedly led to believe that the clinical studies would yield promising results. However, the complaint states that the reality was quite different, with significant statistical failures negatively impacting shareholder confidence.
Details of the Class Action
Running from August 3, 2023, to December 26, 2025, the class action, known as Bailey v. Ultragenyx Pharmaceutical Inc., emphasizes that investors who suffered substantial losses during this period are encouraged to come forward. Furthermore, the lawsuit cites a lack of disclosure about the significant risks associated with the Phase III Orbit study, which ultimately did not produce the anticipated results.
The Impact of Recent Announcements
On July 9, 2025, Ultragenyx announced that their Phase III Orbit study did not achieve the required statistical significance, leading to a more than 25% drop in stock value. Investors were shocked when, shortly after, on December 29, the company confirmed that both the Phase III Orbit and Cosmic studies failed against their primary endpoints. This news resulted in an even sharper decline of over 42% in Ultragenyx's stock price, raising concerns among investors and prompting action from law firms like Robbins Geller.
What Should Investors Consider?
Investors who believe they have been affected are encouraged to consider their options. The Private Securities Litigation Reform Act allows investors who purchased shares during the specified Class Period to seek the appointment as lead plaintiffs in the class action. This could provide an opportunity to represent fellow investors in the actions against Ultragenyx.
Getting Involved and Next Steps
If you are an investor with significant losses related to Ultragenyx shares during the Class Period, it is essential to stay informed about your rights. You may wish to provide your information to participate in the class action or contact attorney J.C. Sanchez of Robbins Geller for more details on how to proceed. They can provide guidance on the status of the lawsuit and the potential for recovering losses.
About Robbins Geller
Robbins Geller Rudman & Dowd LLP is a renowned law firm in the field of securities litigation, consistently ranked among the top firms for their ability to recover billions for investors. With a dedicated team of 200 attorneys, they have secured landmark recoveries in numerous cases, including some of the largest in history. Their ongoing commitment to fighting for investor rights makes them a trusted choice for individuals affected by securities fraud.
Frequently Asked Questions
What is the Ultragenyx class action lawsuit about?
The class action lawsuit addresses misleading statements made by Ultragenyx regarding their treatment for OI and the subsequent financial losses experienced by investors.
How can I participate in the lawsuit?
If you purchased Ultragenyx stock during the Class Period and suffered losses, you can provide your information to be considered as a lead plaintiff.
What are the key dates for the Class Period?
The Class Period runs from August 3, 2023, to December 26, 2025. Anyone who purchased shares during this timeframe may be eligible to join the lawsuit.
Who can I contact for more information?
For more details, you can contact attorney J.C. Sanchez of Robbins Geller at 800-449-4900, or reach out to them via their website.
What should I do if I'm affected by this situation?
It's recommended to stay informed about the lawsuit proceedings. Consider contacting legal counsel for guidance on how to navigate the implications of the class action.
